Neuropsychiatric Adverse Events with Monoclonal Antibodies Approved for Multiple Myeloma: An Analysis from the FDA Adverse Event Reporting System

• Κύριοι συγγραφείς: Giuseppe Cicala (Συγγραφέας), Giulia Russo (Συγγραφέας), Vincenza Santoro (Συγγραφέας), Tindara Franchina (Συγγραφέας), Nicola Silvestris (Συγγραφέας), Mariacarmela Santarpia (Συγγραφέας), Edoardo Spina (Συγγραφέας), Maria Antonietta Barbieri (Συγγραφέας)
• Μορφή: Βιβλίο
• Έκδοση: MDPI AG, 2024-09-01T00:00:00Z.
• Θέματα: article
• Διαθέσιμο Online: Connect to this object online.

<b>Background/Objectives</b>: Monoclonal antibodies (mAbs) have revolutionized multiple myeloma (MM) treatment. However, post-marketing data on their neuropsychiatric safety are limited. This study aimed to evaluate neuropsychiatric adverse events (AEs) related to mAbs used for MM throug...